Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Terumo, Takeda To Co-promote Narcotic Formulations
Terumo and Takeda have announced that the two companies will initiate the co-promotion of ethical narcotic formulations in October, which is manufactured and marketed by Takeda in Japan.
Terumo and Takeda have announced that the two companies will initiate the co-promotion of ethical narcotic formulations in October, which is manufactured and marketed by Takeda in Japan.
FDA has accepted to review Takeda’s supplemental new drug application (sNDA) based on long-term overall survival (OS) data from the VISTA 1 trial. The study examined the use
Vical Incorporated (Vical) has reported the issuance of US Patent No. 7,582,613 covering Vaxfectin-formulated DNA vaccines for influenza. The company said that the patent provides broad coverage for
Algeta has entered into a global agreement with Bayer for the development and commercialisation of the former’s first-in-class alpha-pharmaceutical, Alpharadin. Alpharadin is Algeta’s lead cancer therapeutic. It is
OSI Pharmaceuticals has initiated two clinical trials with OSI-906, an oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a phase III, multi-center study that will
Allos Therapeutics has announced that FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are likely to predict
BioSpecifics Technologies has declared results of the pivotal CORD I phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel biologic for the nonsurgical treatment of Dupuytren’s
NOXXON Pharma has received a research grant from Germany’s Federal Ministry of Education and Research (BMBF), under the Ministry’s small-and-medium-enterprise innovation initiative (KMU-Innovativ). The grant was presented to
Carey & Danis, a law firm, has filed four civil lawsuits on behalf of twenty plaintiffs against Johnson & Johnson and Ortho-McNeil Pharmaceutical (Ortho-McNeil), the makers of the
China Sky One Medical has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA)